Performance
Accuracy. Versatility. Reliability.
At OraSure Technologies, we recognize the importance of HIV
testing and ensuring that infected people get diagnosed early and
linked to care. It is a well known fact that early HIV diagnosis
improves patient health outcomes while preventing new infections.
OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test now delivers earlier antibody sensitivity. Our new materials and process improvements have gained critical detection days from initial infection with comparability to 3rd generation automated EIAs.
OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test now delivers earlier antibody sensitivity. Our new materials and process improvements have gained critical detection days from initial infection with comparability to 3rd generation automated EIAs.
Delay in days of detection with seroconversion specimens
New performance data demonstrates earlier detection in seroconversion panels when compared to 3rd generation EIA.OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test was compared against the BioRad GS HIV-1/2 Plus O 3rd Generation automated assay, with over 200 samples across 23 different seroconversion panels. The results are clear.The performance of the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test is within 1.5 days of 3rd generation testing. This is a significant improvement from our original product launched in 2002.
Identifying HIV from early IgM antibodies!
- OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test uses colloidal gold Protein A conjugate which binds to human IgM antibodies.
- The OraQuick ADVANCE® Test identified 14 out of 16 IgM reactive seroconversion panel members.
- The OraQuick ADVANCE® Test performance demonstrates 3rd generation performance with detection of Igm and IgG antibodies.
i) Complete data found in OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test package insert
ii) IgM antibody panels identified from: Moshgabadi, N. et al. Sesitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its ability to detect HIV gp 41 IgM antibodies; Data presented at 2017 NMA Conference Philadelphia, PA.
ii) IgM antibody panels identified from: Moshgabadi, N. et al. Sesitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its ability to detect HIV gp 41 IgM antibodies; Data presented at 2017 NMA Conference Philadelphia, PA.
| Predominantly anti-HIV-1 IgM Seroconverters Sample | OraQuick ADVANCE® Rapid HIV-1/2 Anitbody Test Line Response |
|---|---|
| 914-01 | R |
| 914-02 | R |
| 914-03 | R |
| 924-08 | R |
| 925-05 | R |
| 925-06 | R |
| 927-03 | R |
| 928-02 | R |
| 934-02 | R |
| 934-03 | R |
| 938-03 | R |
| 940-04 | R |
| 940-05 | R |
| 943-06 | NR |
| 944-05 | R |
| 950-04 | NR |
| Red denotes IgM only samples | |
NEW OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test establishes sesitivity equivalent to 3rd generations EIAs
OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
the early HIV antibody detection test for recent infection*
Accuracy
- >99% sensitivity
- >99.95% specificity from "Real World" data
- Comparable to 3rd generation lab-accurate results
Versatility
- Ability to batch test
- Multiple specimen types including oral fluid, fingerstick & venipuncture whole blood, and plasma
Reliability
- CLIA-waived
- Proven performance with over 30 million test worldwide
- High positive predictive value; minimal false positives
* Refer to the package insert for Warnings and Precautions.
